Drugs / NC-4016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03168035 | Nov 2013 → Apr 2017 | cancer of unknown primary site, lymphoma | NanoCarrier Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NC-4016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03168035 ↗ |
| Route | Intravenous | “NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks.” NCT03168035 ↗ |